Abstract: Physicians prescribing drugs are routinely confronted with the balance between efficacy and toxicity. Pharmacogenetics involves the study of how inheritance influences response to drugs, and its goal is to enable the appropriate selection of these individuals, thus eliminating unpredictable responses. Pharmacogenetics can be used to identify target populations that either will have minimal benefit or a better outcome including better survival or improvement in surrogate end points. As we move towards common use of targeted therapies, the future of medicine will involve an examination of the interplay between multiple genetic factors, as the response to drugs is likely to be complex and polyfactorial especially in chronic diseases. There has already been some success in situations where single genes play a large role in the overall drug response, and this is discussed with reference to commonly used cytotoxics and antiretrovirals, encompassing the major principles of pharmacogenetics.
There is significant heterogeneity in the efficacy and toxicity of chemotherapeutic and anti-retroviral agents and these differences are consistently observed across human populations. Administration of identical doses of these agents to a population of patients results in a range of toxicity, from no side effects to unusual lethal events [1] [2] [3] . While many patient related clinical variables have been associated with drug response, such as age, ethnic origin, gender, organ impairment and function, genetic differences in drug disposition and drug targets can have as great an impact on treatment outcome, as can lifestyle factors such as diet and tumour biology [4] [5] [6] [7] [8] [9] .
There are however few examples where the differences have been exploited in routine clinical practice. Many remain sceptical about the usefulness of genetics in targeting individual therapies, and there are a lack of studies that examine patients by treatment interactions as a secondary end-point [10] . It is clear however that pharmacogenetics has enormous potential to revolutionise the use of many medications, particularly in oncology, as rapid systemic toxicity and unpredictable efficacy is often the hallmark of treatment [11] .
While anti-retroviral medications are not considered as toxic, they are routinely prescribed for a longer duration as the mortality and morbidity of infected patients has been dramatically reduced, as a result of the introduction of highly active anti-retroviral therapy (HAART) in established market economies [12, 13] . Prolonged daily virally suppressive therapy for many years results in a high likelihood of chronic toxicity [14, 15] . By increasing our ability to prospectively identify patients at risk for severe toxicity, or those likely to benefit from a particular therapy, pharmacogenetics promises to help us move towards the ultimate goal of individualised treatment [16] .
Every gene has some degree of sequence polymorphism, and determining which polymorphisms are relevant for predicting patient response to chemotherapy represents a major challenge with enormous clinical utility [17] . However, as the mechanism of action of these prescribed agents is known, polymorphisms in candidate genes likely to influence drug response can be identified [11] . The prediction of treatment outcome based on gene polymorphisms is now becoming possible, but this is not used routinely at this time and debate centres around how it can be integrated into patient care. This review will discuss clinically relevant examples of pharmacogenetics in reference to commonly used cytotoxic drugs. The relevance of host pharmacogenetics to HIV is also discussed, though concentration focuses on human genes, and does not debate the important role of the infecting HIV strain's genotype or phenotype.
ANTIRETROVIRAL AGENTS

Hypersensitivity Reactions
Abacavir, a nucleoside-reverse-transcriptase inhibitor (NRTI), is commonly used as part of HAART regimens in the treatment of chronic HIV-1 infection. Approximately 5% of individuals treated with abacavir containing regimens develop hypersensitivity reactions which can be fatal in rare cases [18] . These hypersensitivity reactions have been well characterised over recent times; symptoms usually appear within the first six weeks of therapy, commonly including a fever, rash and gastrointestinal symptoms. Despite a clear clinical description of these reactions, the use of abacavir in clinical practice still poses a difficult challenge in differentiating abacavir hypersensitivity reactions from other drug reactions commonly encountered when managing HIV patients on HAART, such as rashes and hypersensitivity reactions observed with the use of other classes of antiretroviral therapy. For instance, rashes and fevers are associated with the use of the non-nucleoside-reversetranscriptase-inhibitors (NNRTI) [19] . Meta-analysis of several studies suggest there may be a genetic component to abacavir hypersensitivity reactions. A decreased incidence of abacavir hypersensitivity has been observed in individuals of black race [20] , and familial reports to this reaction have also been observed [21] .
Recently, Mallal et al. have described an association between human leucocyte antigen (HLA) markers and abacavir hypersensitivity reactions in Perth, Western Australia [22] . HLA typing was performed in the first 200 participants exposed to abacavir. Based on a clinical diagnosis, abacavir hypersensitivity was definite in 18 cases after at least six weeks of therapy. HLA-B*5701 was present in a significantly higher proportion of abacavirhypersensitive patients than in abacavir-tolerant patients, as was the combination of HLA-DR7 and HLA-DR3. The presence of these three alleles had a positive predictive value for abacavir hypersensitivity of 100% and a negative predictive value of 97% (Table 1) .
However, this study was performed in a predominantly Caucasian population, and further studies in abacavir exposed cohorts from a range of ethnic and racial populations are required to confirm these findings in order to assess the predictive value of this genetic test for this syndrome. Also, with a lower observed incidence of abacavir hypersensitivity reactions in individuals of black race, other HLA types may be associated with this reaction.
Nevirapine, a NNRTI, is also associated with a hypersensitivity reaction. This commonly involves fever, hepatitis and rash [23] with rare fatal outcomes. Lower pretreatment CD4+ lymphocyte counts are associated with a reduced rate of these reactions. As may therefore be expected, a high rate of nevirapine reactions are observed in HIV-negative individuals exposed to nevirapine in prophylactic regimens.
One study has assessed associations between host genetic factors (HLA type) and immunological factors (CD4+ lymphocyte count) and the incidence of nevirapine hypersensitivity reactions [24] . Again in Western Australia, a cohort of HIV-1 positive individuals exposed to nevirapine in whom hypersensitivity reactions did or did not develop after at least six weeks of therapy were included in the analysis. Fourteen individuals developed a hepatotoxic or multi-system reaction out of 209 individuals. This group had a significantly higher CD4+ lymphocyte percentage (odds ratio 5.5, p=0.003) and percentage carriage of the HLA-DRB1*0101 haplotype (odds ratio 4.8, p=0.01). However, no significant HLA associations were observed in association with individuals who developed an isolated rash thought to be associated with nevirapine therapy.
This interesting data supports the hypothesis that the immunological recognition to nevirapine-specific antigens are CD4+ lymphocyte count dependent and closely associated with genetic susceptibility. Again, in this cohort, 83% of patients were of Caucasian origin and further studies are needed to confirm these associations.
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR PLASMA DRUG EXPOSURE
The NNRTIs are commonly prescribed as first line HAART in HIV-1 infected individuals. High degrees of inter-patient variability plasma drug exposure have been described for both the currently available NNRTIs, efavirenz and nevirapine [25] . The NNRTIs are predominantly metabolised by the cytochrome P450 iso-enzyme group, mainly via the CYP-2B6 [26] . This iso-enzyme is characterised by wide inter-individual variability probably due to genetic polymorphisms and other environmental factors such as exposure to drugs and foods that act as inducers or inhibitors [27, 28] . Of interest, plasma clearance of efavirenz appears slower in African-Americans than in European-Americans, which once again may be due to genetic polymorphisms [29] .
The consequence of low NNRTI plasma drug exposure is the risk of a lack of HIV viral suppression and the subsequent development of drug resistant species. The consequence of high NNRTI plasma drug exposure is the potential greater incidence of drug toxicity, namely central nervous system toxicity, commonly observed with efavirenz therapy. Two recent studies have described significant associations between CYP-2B6 genotype and NNRTI plasma exposure and toxicity [30, 31] . One report described the CYP-2B6 G516T polymorphism to be commoner in African-Americans than European-Americans (20% versus 3%) and to be associated with greater efavirenz plasma exposure. Of importance, this genotype was associated with an increase in the incidence of central nervous system toxicity after one week of efavirenz therapy (p=0.036) [30] .
A Swiss study also assessed associations of this allele and NNRTI plasma exposure [31] . The CYP-2B6 G516T variant was present in 26% of individuals enrolled into 'The genetics project' of the Swiss HIV Cohort Study and were receiving a NNRTI. Geometric mean plasma exposure of efavirenz and nevirapine were 3 fold and 1.7 higher in those homozygous for the allele respectively. Sleep disturbance was associated with both efavirenz plasma exposure and the CYP-2B6 G516T variant.
This genotype may prove to be important for identifying individuals at risk for high levels of efavirenz and patients most likely to develop associated central nervous system toxicity and may be of use in the future as a complementary assessment along with plasma drug concentration measurement when individualising patient therapy. 
HYPERBILIRUBINAEMIA
The HIV-protease inhibitors (PI) were the first class of agents, when used along with NRTIs, to show a reduction in morbidity and mortality associated with HIV disease [32] . Two of the currently licensed HIV-PI, atazanavir and indinavir have been associated with asymptomatic unconjugated hyperbilirubinaemia in 5-15% and 10% of patients respectively [33, 34] . This adverse event is associated clinically with scleral icterus and clinical jaundice, is unpleasant for patients on HAART and is associated with treatment interruptions and changes to antiretroviral therapy. Bilirubin is cleared from the circulation by the liver where it is conjugated with glucuronic acid to form watersoluble metabolites. This glucuronidation reaction is mediated by the microsomal enzyme bilirubin UDPglucuronosyltransferase (UGT). A total of 15 human UGT isoforms have been identified [35] . Metabolism of atazanavir and indinavir is primarily through the cytochrome P450-3A4 iso-enzyme. However, they may also serve as substrates for UGT. Therefore, elevated serum bilirubin levels may result from an inhibitory effect of these agents on bilirubin conjugation, and hyperbilirubinaemia may be most pronounced in individuals with impaired bilirubin metabolism. One common example of this is Gilbert's syndrome affecting 5-10% of the general population [36] .
In vitro studies have demonstrated that indinavir causes hyperbilirubinaemia by competitively inhibiting UGT [37] . Hyperbilirubinaemia has been observed more frequently in individuals with the Gilbert allele exposed to indinavir [37] .
Atazanavir is a new PI and to date, there are no data on associations of UGT polymorphisms and the incidence of hyperbilirubinaemia with atazanavir. Further knowledge of these polymorphisms may be of use in tailoring individual patient's treatment on atazanavir containing regimens in the future.
CANCER CHEMOTHERAPY Thiopurines
Thiopurines are a family of drugs that includes mercaptopurine (a daily component of maintenance therapy for childhood acute lymphoblastic leukaemia treatment), thioguanine (used to treat acute myeloblastic leukaemias), and azathioprine (a commonly prescribed immunosuppressant used in solid organ transplants, rheumatic disease, and dermatological disorders). The principal cytotoxic mechanism of these agents is the incorporation of thioguanine nucleotides (TGN) into DNA ( Fig. 1) . Thus, thiopurines are inactive pro-drugs that require metabolism to TGN to exert cytotoxicity. This activation is catalysed by multiple enzymes, the first of which is hypoxanthine phosphoribosyl transferase (HPRT). Thiopurine methyl transferase (TPMT) methylates 6 mercaptopurine and 6 thioguanine inactivating them, whilst hypoxanthine guanine phosphoribosyl transferase (HGPRT) activates these cytotoxics to thioguanine nucleotides which are incorporated into DNA [38] [39] [40] .
Ten percent of the population is heterozygous +/-for a TPMT polymorphism, which reduces activity and 0.3% are homozygous -/-. These polymorphisms of TPMT are assocated with increased toxicity with 6MP and 6TG and an increased risk of secondary cancers following these agents, particularly a high risk of gliomas following prophylactic cranial irradiation with 6TG or 6MP as part of maintenance therapy for childhood ALL. Three single nucleotide polymorphisms (SNPs) account for >90% of these TPMT mutants and are easily identified genetically [41, 42] . Similarly, the Lesch-Nyhan syndrome in which there is an X-linked recessive mutation of HGPRT is associated with an inability to metabolise 6MP and 6TG to their active phosphates. Although these mutations are far rarer, they markedly reduce the activity of 6MP and 6TG [43, 44] .
Alternatively, these agents can be inactivated via oxidation by xanthine oxidase (XO) or via methylation by thiopurine methyltransferase (TPMT) [45] . TPMT catalyses the S-methylation of the thiopurine agents azathioprine, mercaptopurine, and thioguanine, thereby shunting drug away from TGN formation.
TPMT activity is highly variable and polymorphic in all large populations studied to date; approximately 90% of individuals have high activity, 10% have intermediate activity, and 0.3% have low or no detectable enzyme activity. While eight TPMT alleles have been identified, three alleles (TPMT*2, TPMT*3A, TPMT*3C) account for about 95% of intermediate or low enzyme activity cases. All three alleles are associated with lower enzyme activity due to enhanced rates of proteolysis of the mutant proteins. The presence of TPMT*2, TPMT*3A, or TPMT*3C is predictive of TPMT activity; patients heterozygous for these alleles all have intermediate activity and subjects homozygous for these alleles are TPMT deficient. Numerous studies have shown that TPMT-deficient patients are at very high risk of developing severe haematopoietic toxicity if treated with conventional doses of thiopurines and moreover that patients who are heterozygous at the TPMT locus are at intermediate risk of dose-limiting toxicity. These studies demonstrate that the influence of TPMT genotype on haematopoietic toxicity is most dramatic for homozygous mutant patients, but is also of clinical relevance for heterozygous individuals, which represent about 10% of patients treated with these medications. The remaining 90% of the population carry two wild-type TPMT alleles; these individuals have full TPMT activity and do not require dose reduction. By using PCRbased assays to detect the three signature mutations in these alleles, a rapid and relatively inexpensive assay is available to identify >90% of all mutant alleles. These results can then be prospectively used to determine safe starting doses for thiopurine therapy [46] [47] [48] [49] [50] [51] [52] .
5-FLUOROURACIL
5-Fluorouracil (5-FU) is a uracil analogue that is used to treat solid tumours, such as colorectal and breast cancer. The most widely known pharmacogenetic effect in cytotoxic therapy is the rare deficiency of dihydropyrimidine dehydrogenase (DPD) due to splice variant polymorphisms of the gene on chromosome 1p22 leading to deficient or absent enzyme activity. This is associated with failure to catabolise 5-FU, and markedly enhanced toxicity with standard doses has been reported. DPD converts 5-FU to the inactive dihydro5-FU and inactivity of this pathway leads to increased levels of 5F-dUMP, the active moiety which inhibits thymidine synthetase. The polymorphism in DPD is an SNP in exon 14 which disrupts splicing leading to a splice between exons 13 & 15 and loss of exon 14 (Fig. 2 ) [17, 53, 54] . This product has no enzymatic activity and 3% of the population is heterozygous for this SNP. Patients with low DPD activity cannot effectively inactivate 5-FU, leading to excessive amounts of 5-FdUMP, causing gastrointestinal, haematopoietic, and neurological toxicities that are potentially fatal.
The molecular basis of genetic DPD deficiency is complex [55, 56] . To date, at least 20 mutations associated with reduced DPD activity have been reported. In the general population, 3-5% of individuals are heterozygous carriers of mutations that inactivate DPD, and 0.1% of individuals are homozygous for mutations that inactivate DPD. The most common inactivating allele of DPD accounts for about 50% of known non-functional alleles, and is caused by a G A transition at the invariant GT splice donor site flanking exon 14 of the DPYD gene. This allele (known as DPYD*2A) causes the skipping of exon 14, and leads to the production of a non-functional protein. The DPYD*2A allele has been associated with severe toxicity and fatal outcomes of 5-FU treatment in some studies. However, DPYD*2A is not the only mechanism for severe 5-FU toxicity. Indeed, many patients with severe 5-FU toxicity have no detected mutations in the coding region of the D P Y D gene. The intricate nature of the molecular mechanisms controlling DPD activity in vivo complicate the application of DPD pharmacogenetics for the prospective identification of patients likely to experience severe 5-FU toxicity [57] [58] [59] .
Genetic polymorphisms in the gene encoding thymidylate synthase (also known as TYMS and TS) have also been shown to influence response to 5-FU therapy. One example is the thymidylate synthase enhancer region (TSER*2/3) polymorphism, which affects the 5' untranslated region and alters enhancer activity and therefore transcriptional activity. The 5'UTR includes a 21 base pair repeat: if there are 2 copies of this repeat, the activity of TS is lower and hence the response to 5-FU higher than if there are 3 copies of this repeat sequence (Fig. 3) . TSER*3/3 homozygotes have 3-6 times higher mRNA and protein levels than 2/2 homozygotes.
The expression of T S is controlled in part by a polymorphism characterised by a multiple number of tandem repeats of a 28-bp sequence in the 5'-promoter enhancer region (TSER) of the gene. Alleles containing two, three, four, five, and nine copies of the repeated sequence have been described (TSER*2, TSER*3, TSER*4, TSER*5, and TSER*9), with TSER*2 and TSER*3 being the predominant alleles in all populations studied to date. Multiple in vivo studies have shown that increasing the number of repeats leads to an increase in TS mRNA levels and protein expression. The combined genotyping of DPYD and TSER functional variants might be useful in selecting patients who are likely to tolerate and respond to 5-FU therapy. This is particularly important because of the availability of other active antitumour agents (i.e., irinotecan, oxaliplatin), which can be used in combination with or in place of 5-FU if high TS or deficient DYPD are detected [60, 61] .
IRINOTECAN
Irinotecan is a topoisomerase I inhibitor that is used to treat various solid tumours, with FDA approval for the treatment of advanced colorectal cancer. Irinotecan itself is a prodrug, which requires activation by carboxylesterase to its active metabolite, SN-38. Diarrhoea and leucopenia are the dose-limiting toxicities of irinotecan and are associated with increased levels of SN-38 [17, 53] .
The clinical pharmacogenetics of irinotecan treatment is mainly focused on polymorphic glucuronidation of SN-38 by UGT1A1, analogous to the situation observed with antiretrovirals [37] . UGT1A1 expression is highly variable, and studies have shown an interpatient variability in the rate of SN-38 glucuronidation of up to 50-fold. The UGT1A1 promoter region contains a number of TA base repeats, with between five and eight repeats observed in the general population. A six-TA repeat allele is the most common, and an inverse relationship exists between the number of repeats and the expression of UGT1A1. The presence of seven repeats, instead of the wild-type number of six, results in the variant allele UGT1A1*28. The UGT1A1*28 allele is associated with reduced UGT1A1 expression, and leads to reduced SN-38 glucuronidation [54, [62] [63] [64] .
Two seminal papers have shown that the UGT1A1*28 allele leads to significantly increased levels of the active metabolite SN-38, and an increased chance of developing diarrhoea and leucopenia during irinotecan therapy, and also suggest that determination of the UGT1A1 genotypes may be clinically useful for predicting severe toxicity to irinotecan [65, 66] .
PLATINUM AGENTS
Platinum agents (cisplatin, carboplatin, oxaliplatin) inhibit cellular replication by forming inter-and intrastrand helix-deforming DNA adducts. Resistance to platinum agents can occur through decreased drug accumulation, detoxification through conjugation, enhanced tolerance to platinum-induced DNA adducts, or enhanced DNA repair. Two recent studies have demonstrated the significance of polymorphisms in DNA excision repair genes for response to chemotherapy with platinum agents [67] . In one study, polymorphisms in the XPD gene (also named ERCC2; an essential member of the nucleotide excision repair pathway) were analysed in patients with metastatic colorectal cancer who were treated with a combination of 5-FU and oxaliplatin [68] . A non-synonomous SNP, altering a lysine to glutamine at codon 751 of the XPD protein, was significantly associated with treatment outcome. The mechanistic explanation for the predictive power of this SNP is not clear. A decreased DNA repair capacity has been described for the lysine variant in women, while a larger study has reported the opposite finding in lung cancer patients. However, while the functional consequence of this SNP may not be known, it may still have relevance as a clinical predictor of platinum agent therapy [69] .
Numerous recent papers demonstrate that polymorphisms in the XRCC1 protein (a protein involved in the repair of single-strand breaks following base excision repair) have also been shown to be associated with platinum agent response [69] [70] [71] [72] [73] [74] [75] . To evaluate the clinical significance of this, one study used polymerase chain reaction-restriction fragment length polymorphism to evaluate genetic polymorphisms of the XPD (Asp312Asn) and XRCC1 (Arg399Gln) DNA repair genes in 103 patients with stage III (54%) and IV (46%) non small cell lung cancer treated with platinum-based chemotherapy. While genotypes were not associated with stage, increasing numbers of either XPD or XRCC1 variant alleles were associated with shorter overall survival (P =.003 and P =.07, respectively, by log-rank test). Similarly, when the authors compared combinations of variant alleles across both polymorphisms, they found that a greater number of variant alleles was associated with decreasing overall survival (P =.009, log-rank test). These polymorphisms independently predicted overall survival even after taking into account stage, performance status, and chemotherapy regimen [76, 77] .
Polymorphisms in glutathione (GSH)-dependent enzymes have also been shown to influence response to platinum chemotherapy agents. Polymorphisms of GSTs are common with up to 50% caucasian population having germline homozygous deletions of GSTM1 gene. GSTM1 null polymorphisms have deletion of the entire gene and no enzyme activity. Null carriers have survival and progressionfree survival following paclitaxel and cisplatin for ovarian cancer, as well as decreased risk of relapse following cytotoxic therapy for leukaemia. GSTM3*A is an intronic deletion which confers an increased risk of cisplatin ototoxicity. GSTP1 missense polymorphism is associated with increased survival for 5-FU and oxaliplatin in colorectal cancer. In contrast, GSTP1 null mutants are associated with increased event-free survival in women treated with cyclophosphamide for breast cancer, due to enhanced anticancer drug levels. GSTT1 null gene deletion is associated with susceptibility to tacrine and troglitazone hepatotoxicity. Moreover, GSTT1 deletions are associated with a higher risk of toxic death in children treated with intensive chemotherapy for ALL due to reduced drug metabolism [78] [79] [80] .
OTHER COMPOUNDS
Drug metabolism is the primary route of elimination particularly for lipid soluble agents, and the hepatic endoplasmic reticulum is the main site for enzymes that catalyse phase I and II reactions. Phase I reactions make substrates more polar and therefore less lipid soluble (oxidation, reduction, hydrolysis), whilst phase II reactions conjugate side chains (glucuronate, acetate, sulphate) onto drugs. Phase I reactions may also be necessary to activate prodrugs and such pathways have been understood for some time.
The cytochrome 450 enzyme family (CYP) is responsible for most phase I reactions. CYP isoenzymes are grouped into families (1,2,3 etc) and subfamilies (A,B,C etc). Genetic variants of CYP isoenzymes account for slow and rapid metabolism of drugs. Environmental factors also alter CYP enzyme activity [81, 82] . For example, grapefruit juice inhibits CYP3A4. Polymorphisms of the hepatic P450 cytochrome enzymes also account for pharmacogenetic variation I, the metabolism of cytotoxic drugs. Polymorphisms of these enzymes may also alter the risk of carcinogen induced cancers. For example, an SNP (single nucleotide polymorphism) of CYP17 causes a T to C change in the 5' promoter and creates an SP-1 binding site, which enhances the activity of CYP17, which detoxifies oestrogens. Homozygous women with this CYP17 polymorphism are at a reduced risk of endometrial cancer following oestrogen therapy.
An understanding of these metabolic pathways also enables an appreciation of the interaction between cytotoxics and other drugs examples of which are as follows: inhibition of CYP3A4 by ketoconazole, itraconazole, erythromycin, clarithromycin, or grapefruit juice may result in decreased clearance of etoposide, vinca alkaloids, or irinotecan or decreased activation of ifosfamide; induction of CYP3A4 by corticosteroids, phenytoin, phenobarbital, rifampin, cyclophosphamide, or ifosfamide may result in enhanced clearance of etoposide, vinca alkaloids, or irinotecan or enhanced activation of ifosfamide and inhibition of glucuronyl transferases by valproic acid may result in decreased clearance of SN-38; inhibition of xanthine oxidase by allopurinol may result in decreased clearance of 6-MP and, the inhibition of biliary excretion by cyclosporine A (and other P-glycoprotein inhibitors) may result in decreased clearance of a wide range of agents [17, 62, [83] [84] [85] [86] [87] .
PHARMACOGENETICS IN CLINICAL PRACTICE
One of the key factors in developing improved medicines rests in understanding the molecular basis of the complex diseases that we treated, and there is considerable overlap here between conditions as seemingly diverse as HIV and cancer. Investigation of genetic associations with disease utilising advances in linkage disequilibrium-based whole genome association strategies will provide novel targets for therapy and define relevant pathways contributing to disease pathogenesis. Genetic studies in conjunction with gene expression, proteomic, and metabonomic analyses provide a powerful tool to identify molecular subtypes of disease. Using these molecular data, pharmacogenetics has the potential to impact on the drug discovery and development process at many stages of the pipeline, contributing to both target identification and increased confidence in the therapeutic rationale [53, 54] .
Within a decade, genetic testing is likely to be used in routine clinical practice for guiding the selection of appropriate therapy, and dosage adjustment to increase efficacy and decrease toxicity. Studies mentioned above enable the prospective identification of appropriate dose reductions to reduce the chance of serious toxicity and also facilitate discovering which patients can receive increased doses without harmful side effects. However, at present, many examples of cancer pharmacogenetics are associations between polymorphisms and treatment outcomes that border on statistical significance. In order to move from the bench to the bedside, statistically significant measures of toxicity risk and clinical benefit are required. In order to achieve this, pharmacogenetic studies must be included in randomised phase 3 clinical trials that contain enough patients, and the US Food and Drug Administration is making progress with suggesting study design [16] .
A focussed pharmacogenetic strategy at the preclinical phase of drug development will produce data to inform the pharmacogenetic plan for exploratory and full development of compounds. Opportunities post-approval show the value of large well-characterised data sets for a systematic assessment of the contribution of genetic determinants to adverse drug reactions and efficacy. The availability of genomic samples in large phase IV trials also provides a valuable resource for further understanding the molecular basis of disease heterogeneity, providing data that feeds back into the drug discovery process in target identification and validation for the next generation of improved medicines. Pharmacogenetics offers the potential of developing DNAbased tests to help maximise drug efficacy and enhance drug safety, so long as the predictive ability of such tests can be established by trials.
This has particular implications in the current health care environment, where cost containment and evidence-based initiatives have a significant influence on patient care.
